Comparison of Improvement in 2-Year Survival Rate of Patients with Stage II-III Non-Small Cell Lung Cancer Treated with Different Durations of Chinese Patent Medicine: A Retrospective Cohort Study
Background: Chinese patent medicine is widely used among patients with malignant tumors, and current studies have shown that long-term treatment with Chinese patent medicine is related to improved outcomes of patients. Huisheng Oral Liquid is a kind of Chinese patent medicine with the effects of cur...
Saved in:
Main Authors: | Li Wang (Author), Kegang Jia (Author), Fang Li (Author), Chenxu Zhang (Author), Gang Feng (Author), Jun Du (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of socioeconomic status on cancer staging, survival in non-small cell lung cancer
by: Xianghui Yang, et al.
Published: (2022) -
Management of stage III non-small-cell lung cancer: rays of hope
by: Floryane Kim, et al.
Published: (2024) -
Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study
by: Mario Ouwens, PhD, et al.
Published: (2021) -
Immunotherapy in inoperable stage III non-small cell lung cancer: a review
by: Natasha A Jain, et al.
Published: (2019) -
Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
by: Guo D, et al.
Published: (2021)